



Agenda | Management Board

67th Meeting

Date **29 June 2023** Chair **Franz Pietsch**

Venue **Lisbon and video conference (Microsoft Teams)**

Thursday, 29 June 2023
9.00 – 17.00 (Lisbon time)

9.00 – 11.00

1. Introduction by the Chair

2. Adoption of the agenda

2.1. Annotated agenda

EMCDDA/01/23 rev1
EMCDDA/02/23

PART I: Exchange of views

3. Exchange of views on the situation concerning cannabis and amphetamines

- 3.1. Presentation by the EMCDDA of the modules of the joint EMCDDA-Europol European Drug Markets Report on cannabis and amphetamines in Europe
- 3.2. Discussion

PART II: Regulation on the European Union Drugs Agency

4. Adoption of the new Regulation on the European Union Drugs Agency

- 4.1. Video statement by Ms Ylva Johansson, Commissioner for Home Affairs
- 4.2. Intervention by the Swedish Presidency of the Council of the European Union
- 4.3. Intervention by the representatives of the European Parliament
- 4.4. Remarks from the EMCDDA Director
- 4.5. Remarks from the Chair of the EMCDDA Management Board

11.00 – 11.15 Break

11.15 – 13.00

PART III: Items for decision and information

5. Preparation for the new Regulation on the European Union Drugs Agency (EUDA):

- 5.1. Update of the EMCDDA implementation plan for the new Regulation on the European Union Drugs Agency (*for information*) EMCDDA/03/23
- 5.2. Procedure for the nomination of the members to the EUDA Management Board (*for endorsement*) EMCDDA/04/23
- 5.3. Procedure for the adoption of the rules of procedure of the EUDA Management Board (*for decision*) EMCDDA/05/23
- 5.4. Procedure to establish the EUDA Scientific Committee (*for decision*) EMCDDA/06/23
- 5.5. Procedure to establish a new list of experts to extend the EUDA Scientific Committee for the purposes of the risk assessment of new psychoactive substances (*for decision*) EMCDDA/07/23
- 5.6. Procedure for the nomination of the EUDA Reitox national focal points (*for endorsement*) EMCDDA/08/23

- | | |
|---|--------------|
| 5.7. Establishment of a working group to discuss the Reitox co-financing <i>(for decision)</i> | EMCDDA/09/23 |
| 5.8. Procedure to establish a network of forensic and toxicological laboratories <i>(for endorsement)</i> | EMCDDA/10/23 |
| 5.9. Outlines of the European Union Drugs Agency branding project <i>(for information)</i> | EMCDDA/11/23 |

13.00 – 14.00 Lunch

14.00 – 17.00

PART IV: Items for decision and information

6. International cooperation:

- | | |
|---|--------------|
| 6.1. Overview on the drugs situation and cooperation with third countries <i>(for information)</i> | |
| - Candidate and potential candidate countries | |
| 6.2. The EMCDDA/IPA 8 project (Instrument for Pre-Accession Assistance) <i>(for information)</i> | EMCDDA/12/23 |
| - European neighbourhood countries <i>(for information)</i> | |
| 6.3. 'EU4 Monitoring Drugs' II project <i>(for information)</i> | EMCDDA/13/23 |
| 6.4. EMCDDA technical cooperation project with Georgia <i>(for information)</i> | EMCDDA/14/23 |
| - Other non-EU countries | |
| 6.5. Mandate for negotiating a Working Arrangement between the EMCDDA and Ecuador <i>(for decision)</i> | EMCDDA/15/23 |
| 6.6. Mandate for negotiating a Working Arrangement between the EMCDDA and Colombia <i>(for decision)</i> | EMCDDA/16/23 |
| 6.7. Mandate for negotiating a Working Arrangement between the EMCDDA and SENDA (Chile) <i>(for decision)</i> | EMCDDA/17/23 |
| 6.8. COPOLAD III project (Cooperation Programme between Latin America, the Caribbean and the EU on Drugs Policies) <i>(for information)</i> | EMCDDA/18/23 |

7. Activity reports:

- | | |
|---|--------------|
| 7.1. Report on the activities of the Chair <i>(for information)</i> | EMCDDA/19/23 |
| 7.2. Report from the Budget Committee <i>(for information)</i> | EMCDDA/20/23 |
| 7.3. Report on the external activities of the Director <i>(for information)</i> | EMCDDA/21/23 |

PART V: Items for decision and information

8. Presentations by the EU Presidencies:

- | | |
|---|--|
| 8.1. Presentation on the conclusions of the Swedish Presidency <i>(for information)</i> | |
| 8.2. Presentation on the programme of the Spanish Presidency <i>(for information)</i> | |

9. Budget and financial issues:

- | | |
|---|--------------|
| 9.1. EMCDDA 2022 final accounts: opinion of the Management Board <i>(for adoption)</i> | EMCDDA/22/23 |
| 9.2. Information on procurements for non-administrative activities of a value greater than EUR 60 000 to implement the 2023 work programme <i>(for information)</i> | EMCDDA/23/23 |
| 9.3. EMCDDA's budget for 2024: Oral report on the state of play by the European Commission <i>(for information)</i> | |

10. Functioning of the Management Board:

- | | |
|--|--------------|
| 10.1. Nomination of an alternate observer for the Pompidou Group of the Council of Europe in Management Board meetings <i>(for decision)</i> | EMCDDA/24/23 |
| 10.2. Planning of meetings for 2024 <i>(for endorsement)</i> | EMCDDA/25/23 |

11. Performance:

- | | |
|--|--------------|
| 11.1. Presentation by the Director on the performance of the EMCDDA in 2022 <i>(for information)</i> | |
| 11.2. State of implementation of the recommendations issued by the Internal Audit Service (IAS) <i>(for information)</i> | EMCDDA/26/23 |

11.3. EMCDDA Action Plan further to the 2023 IAS Audit on coordination between DG HOME and the EU decentralised agencies EMCDDA, EUAA, Europol, CEPOL and eu-LISA (*for endorsement*)

EMCDDA/27/23

12. Prevention and management of conflicts of interest:

12.1. Periodic assessment of the implementation of the EMCDDA Policy for the prevention and management of conflicts of interest for Management Board members, substitutes and observers (*for decision*)

EMCDDA/28/23

13. Any other business

17.00 **Gathering with the EMCDDA staff (Cais do Sodré)**